Literature DB >> 17485504

Amiodarone and bepridil inhibit anthrax toxin entry into host cells.

Ana M Sanchez1, Diane Thomas, Eugene J Gillespie, Robert Damoiseaux, Joseph Rogers, Jonathan P Saxe, Jing Huang, Marianne Manchester, Kenneth A Bradley.   

Abstract

Anthrax lethal toxin is one of the fundamental components believed to be responsible for the virulence of Bacillus anthracis. In order to find novel compounds with anti-lethal toxin properties, we used a cell-based assay to screen a collection of approximately 500 small molecules. Nineteen compounds that blocked lethal toxin-mediated killing of RAW 264.7 macrophages were identified, and we report here on the characterization of the two most potent antitoxic compounds, amiodarone and bepridil. These drugs are used to treat cardiac arrhythmia or angina in humans at doses similar to those that provide protection against lethal toxin in vitro. Our results support a model whereby the antitoxic properties of both drugs result from their ability to block endosomal acidification, thereby blocking toxin entry. Amiodarone was tested in vivo and found to significantly increase survival of lethal toxin-challenged Fischer rats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17485504      PMCID: PMC1913235          DOI: 10.1128/AAC.01184-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo.

Authors:  Jason E Comer; Ashok K Chopra; Johnny W Peterson; Rolf König
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  In vitro inhibition of lysosomal phospholipase A1 of rat lung by amiodarone and desethylamiodarone.

Authors:  K Y Hostetler; J R Giordano; E J Jellison
Journal:  Biochim Biophys Acta       Date:  1988-04-15

3.  Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor.

Authors:  J G Naglich; J E Metherall; D W Russell; L Eidels
Journal:  Cell       Date:  1992-06-12       Impact factor: 41.582

4.  Toxicity of amiodarone on mouse pulmonary endothelial cells cultured with or without alveolar macrophages.

Authors:  Y Futamura
Journal:  J Toxicol Sci       Date:  1996-11       Impact factor: 2.196

5.  Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease.

Authors:  B Guigui; S Perrot; J P Berry; J Fleury-Feith; N Martin; J M Métreau; D Dhumeaux; E S Zafrani
Journal:  Hepatology       Date:  1988 Sep-Oct       Impact factor: 17.425

6.  Effect of amiodarone on cytokine release and on enzyme activities of mouse alveolar macrophages, bone marrow macrophages, and blood monocytes.

Authors:  Y Futamura
Journal:  J Toxicol Sci       Date:  1996-05       Impact factor: 2.196

7.  Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin.

Authors:  K R Klimpel; S S Molloy; G Thomas; S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

8.  Pharmacokinetics of intravenous bepridil in patients with coronary disease.

Authors:  L J Lesko; J R Benotti; J S Alpert; P M Brady; J E McCue; B H Weiner; I S Ockene
Journal:  J Pharm Sci       Date:  1986-10       Impact factor: 3.534

9.  Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.

Authors:  A M Friedlander
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157

10.  Modulation of protein kinase C activity by amiodarone and desethylamiodarone.

Authors:  P J Vig; D Desaiah
Journal:  Neurotoxicology       Date:  1991       Impact factor: 4.294

View more
  13 in total

Review 1.  Designing inhibitors of anthrax toxin.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Expert Opin Drug Discov       Date:  2014-01-22       Impact factor: 6.098

Review 2.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

3.  The overlap of small molecule and protein binding sites within families of protein structures.

Authors:  Fred P Davis; Andrej Sali
Journal:  PLoS Comput Biol       Date:  2010-02-05       Impact factor: 4.475

Review 4.  Novel strategies to combat bacterial virulence.

Authors:  Susan V Lynch; Jeanine P Wiener-Kronish
Journal:  Curr Opin Crit Care       Date:  2008-10       Impact factor: 3.687

5.  Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses.

Authors:  Eugene J Gillespie; Chi-Lee C Ho; Kavitha Balaji; Daniel L Clemens; Gang Deng; Yao E Wang; Heidi J Elsaesser; Batcha Tamilselvam; Amandeep Gargi; Shandee D Dixon; Bryan France; Brian T Chamberlain; Steven R Blanke; Genhong Cheng; Juan Carlos de la Torre; David G Brooks; Michael E Jung; John Colicelli; Robert Damoiseaux; Kenneth A Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

6.  Identification of novel host-targeted compounds that protect from anthrax lethal toxin-induced cell death.

Authors:  Louise H Slater; Erik C Hett; Kevin Mark; Nicole M Chumbler; Deepa Patel; D Borden Lacy; R John Collier; Deborah T Hung
Journal:  ACS Chem Biol       Date:  2013-02-04       Impact factor: 5.100

7.  Chemical genetics reveals a kinase-independent role for protein kinase R in pyroptosis.

Authors:  Erik C Hett; Louise H Slater; Kevin G Mark; Tomohiko Kawate; Brian G Monks; Andrea Stutz; Eicke Latz; Deborah T Hung
Journal:  Nat Chem Biol       Date:  2013-04-21       Impact factor: 15.040

8.  Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.

Authors:  Johnny W Peterson; Scott T Moen; Daniel Healy; Jennifer E Pawlik; Joanna Taormina; Jason Hardcastle; John M Thomas; William S Lawrence; Cindy Ponce; Bagram M Chatuev; Bryan T Gnade; Sheri M Foltz; Stacy L Agar; Jian Sha; Gary R Klimpel; Michelle L Kirtley; Tonyia Eaves-Pyles; Ashok K Chopra
Journal:  Open Microbiol J       Date:  2010-06-03

9.  A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection.

Authors:  Jane P F Bai; Theodore Sakellaropoulos; Leonidas G Alexopoulos
Journal:  Toxins (Basel)       Date:  2017-03-10       Impact factor: 4.546

10.  Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.

Authors:  Ping Jun Zhu; John P Hobson; Noel Southall; Cunping Qiu; Craig J Thomas; Jiamo Lu; James Inglese; Wei Zheng; Stephen H Leppla; Thomas H Bugge; Christopher P Austin; Shihui Liu
Journal:  Bioorg Med Chem       Date:  2009-05-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.